Integrated Cancer Repository for Cancer Research

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-110
SponsorUniversity of Nebraska

About this trial

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Eligibility criteria

Qualifiers

Diagnosis/history of cancer

Risk for developing cancer or suspicious clinical findings

No history of cancer (normal control registry)

Able to provide informed consent

Disqualifiers

Unable to provide informed consent because of cognitive impairment

Non-English or non-Spanish speaking individuals

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators